Inclusion Criteria:

- Histologically proven diagnosis of advanced or metastatic solid tumors for whom
either refractory to standard therapy exists, or for whom treatment with an
investigational agent alone or in combination with docetaxel, paclitaxel,
carboplatin, or paclitaxel plus carboplatin is appropriate;

- ANC≥ 1.5 x 109/L;

- Hgb ≥ 9.0 g/L;

- PLT ≥ 100,000/mm3;

- Total bilirubin ≤ 1.5;

- Willing and able to remain in the clinic for at least 4 days

Exclusion Criteria:

- Patients with CNS and/or leptomeningeal disease metastases allowed on the study
unless asymptomatic and not requiring corticosteroid therapy. Patients having any
clinical signs of CNS metastases must have a CT or MRI of the brain performed to rule
out CNS metastases in order to be eligible for study participation. Patients who
have had brain metastases surgically removed or irradiated with no residual disease
confirmed by imaging are allowed;

- Patients unable to undergo intravenous infusion;

- Patients with a Baseline 12-lead EGC QTc of >450 msec;

- Radiotherapy in less than two (2) weeks prior to study entry;

- A history of noncompliance to medical regimens or inability or unwillingness to
return for all scheduled visits

Other protocol-defined inclusion/exclusion criteria may apply